Skip to Content

James L. Murray, MD, MPH

Present Title & Affiliation

Primary Appointment

Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Currently, I am a Professor of Cancer Medicine with over 20 years experience in the treatment of breast cancer. My research interests include the immunotherapy of breast cancer, and I am chair or co-chair of several pivotal clinical trials of therapeutic and preventive vaccines in breast cancer. Having recently obtained my Masters in Public Health with a focus in cancer prevention, I am working in the Division of Epidemiology to define genetic risk factors which predispose patients to more aggressive forms of breast cancer with an emphasis on genes involved in inflammation. Most importantly, as a busy clinician I am continuously striving to offer my patients optimal breast cancer treatments in a caring and compassionate manner, with the ultimate goal of prolonging life and eventually eradicating this disease.

Education & Training

Degree-Granting Education

1972 University of Indiana, Indianapolis, IN, MD
1968 Colorado College, Colorado Springs, CO, BA, Science

Postgraduate Training

2004-2008 Master in Public Health, Epidemiology and Disease Control, The University Of Texas School of Public Health, Houston, TX, Tommy C. Douglas, PhD and Melissa Bondy, Ph.D., Thesis Advisors
1975-1978 Fellowship, Hematology/Oncology, Ohio State University, Columbus, OH
1973-1975 Residency, Internal Medicine, University of Indiana, Indianapolis, IN
1972-1973 Rotating Internship, St. Joseph's Hospital, Denver, CO

Board Certifications

9/1978 Hematology
10/1977 Medical Oncology
6/1976 Internal Medicine


Academic Appointments

Director, Department of Bioimmunotherapy, Clinical Immunology Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002-present
Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2002-2004
Director, Bioimmunotherapy, Immunotherapy & Vaccine Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993-present
Associate Professor, Medicine and Associate Internist, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1987-1993
Faculty Associate, Department of Clinical Immunology and Biological Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1982-1983
Assistant Member, Oklahoma Medical Research Foundation, Oklahoma City, OK, 1978-1982
Assistant Professor, University of Oklahoma, College of Medicine, Oklahoma City, OK, 1978-1982
Instructor, Ohio State University, Columbus, OH, 1975-1978

Administrative Appointments/Responsibilities

Chairman, Membership Committee, International Society for Biological Therapy of Cancer, Milwaukee, WI, 2002-2003
Member, Board of Directors, Society of Biological Therapy, Milwaukee, WI, 2001-2002

Selected Publications

Peer-Reviewed Original Research Articles

1. Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs. e-Pub 5/2015. PMID: 25947565.
2. Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer. e-Pub 3/2015. PMID: 25913905.
3. Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 120(13):1932-8, 7/2014. e-Pub 3/2014. PMID: 24677057.
4. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol 25(6):1122-7, 6/2014. e-Pub 3/2014. PMCID: PMC4037860.
5. Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK. Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. J Cancer 5(5):351-9, 2014. e-Pub 3/2014. PMCID: PMC3982182.
6. Chen JQ, Xiao L, Litton JK, Zhou R, Wu Y, Sun X, Zhang H, Sahib AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Murray JL, Radvanyi LG. Prognostic value of the trichorhinopharyngeal syndrome-1 (TRPS-1) gene in early-stage breast cancer. Annals of Oncol 24(10):2534-42, 10/2013. PMCID: PMCPMC3784330.
7. Murray JL, Thompson P, Yoo SY, Do KA, Pande M, Zhou R, Liu Y, Sahin AA, Bondy ML, Brewster AM. Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early-stage breast cancer. Breast Cancer Res Treat 138(3):917-24, 4/2013. e-Pub 3/2013. PMCID: PMC3746974.
8. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol 71(1):63-72, 1/2013. e-Pub 9/2012. PMCID: PMC3536885.
9. Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, Miles D. Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial. J Cancer 4(7):577-84, 2013. e-Pub 8/2013. PMCID: PMC3753533.
10. Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378-84, 5/2012. e-Pub 10/2011. PMID: 22006179.
11. Wu RC, Liu S, Chacon JA, Wu S, Li Y, Sukhumalchandra P, Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi LG. Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype. Clin Cancer Res 18(9):2465-77, 5/2012. e-Pub 2/2012. PMCID: PMC3343210.
12. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 30(7):729-34, 3/2012. e-Pub 1/2012. PMID: 22291085.
13. Brewster AM, Thompson P, Sahin AA, Do K, Edgerton M, Murray JL, Tsavichidis S, Zhou R, Liu S, Zhang L, Mills G, Bondy M. Copy imbalances between screen and symptom-detected breast cancers and impact on disease-free survival. Cancer Prev and Res 4(10):1609-1616, 10/2011. e-Pub 7/2011. PMCID: PMCPMC3188338.
14. Chen JQ, Bao Y, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Katz RL, Sahin A, Bondy M, Murray JL, Radvanyi L. Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer. Horm Cancer 2(2):132-43, 4/2011. PMID: 21761336.
15. Miles D, Roche H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwel D, Parker J, Mayordormo J, Tres A, Murray JL, Ibrahim NK. Phase III multicenter trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16(8):1092-1100, 2011. PMCID: PMCPMC3228158.
16. Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Erlandsson F, Acton G, Pegram M. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clinical Cancer Research 17(21):6822-6830, 2011. PMID: 21878535.
17. Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. Public Library of Science-one 6(8):e23543, 2011. PMCID: PMCPMC3155554.
18. Hortobagyi GN, young RR, Karwal M, Ibrahim NK, Hermann R, Murray JL, Watkins SP, Gore Jr. I. A phase II study of a fixed combination of UFT (uracil+ftorafur) and Leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer 116(10):2301-2306, 2010. PMID: 20225231.
19. Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. British Journal of Cancer 103(9):1331-1334, 2010.
20. Martinez ME, Gutierrez-Millan LE, Bondy M, Daneri-Navaro A, Meza-Montenegro MM, Anduro-Corona I, Aramburo-Rubio MI, Bladeras-Peña LMA, Barragan-Ruiz JA, Brewster A, Caire-Juvera G, Castro-Cervantes JM, Zamudio MAC, Cruz G, Del Toro-Arreola A, Edgerton ME, Flores-Marquez MR. Franco-Topete RA, Garcia H, Gutierrez-Rubio SA, Hahn K, Jimenez-Perez LM, Komenaka IK, Bujanda ZAL, Lu D, Moran-Villela G, Murray JL, Nodora JN, Oceguera-Villanueva A, Martinez MAO, Michel LP, Quintero-Ramos A, Sahin A, Shim JY, Stewart M, Vazquez-Camacho G, Wertheim B, Zenuk R, Thompson P. Comparative Study of Breast Cancer in Mexican and Mexican-American Women. Health 2(9):1040-1048, 2010.
21. Chen JQ, Litton J, Xiao L, Zhang HZ, Warneke C, Wu Y, Shen X, Wu S, Sahin A, Katz R, Bondy M, Hortobagyi G, Berinstein N, Murray JL, Radvanyi L. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. Hormones and Cancer 1(1):21-33, 2010.
22. Holmes JP, Benavides L, Gates JD, Carmichael MG, Hueman TM, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE. Results of the first phase I clinical trial of the novel Ii-Key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 26(20):3426-33, 2008. PMID: 18612158.
23. Brewster AM, Do K-A, Thompson PA, Hahn KM, Sahin AA, Cao Y, Stewart MM, Murray JL, Hortobagyi GN, Bondy ML. The relationship between epidemiological risk factors and breast cancer recurrence. JCO 25(28):4438-44, 2008. PMID: 17785707.
24. Efferson CL, Tsuda N, Kawano K, Nistal-Villan E, Sellappan S, Yu D, Murray JL, Garcia-Sastre A, Ioannides CG. Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. J Virol 80(1):383-94, 2006. PMID: 16352563.
25. Kawano K, Efferson CL, Peoples GE, Carter D, Tsuda N, Murray JL, Ioannides CG. Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death. Cancer Res 65(7):2930-7, 2005. PMID: 15805296.
26. Murray JL, Gillogly M, Kawano K, Efferson CL, Lee JE, Ross M, Wang X, Ferrone S, Ioannides CG. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res 64(15):5481-8, 2004. PMID: 15289358.
27. Schilder, R, Molina A, Bartlett N, Witzig TE, Gordon L, Murray JL, Spies S, Wang H, White CA, Wiseman G. Follow-up results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-cell Non-Hodgkins Lymphoma and Mild Thrombocytopenia. Cancer Biother Radiopharm 19(4):478-481, 2004.
28. Zhang WB, Wang ZX, Murray JL, Fujii N, Broach J, Peiper SC. Functional expression of CXCR4 in S. Cerevisiae: Development of tools for mechanistic and pharmacologic studies. Ernest Schering Research Foundation Workshop(45):125-152, 2004.
29. Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE, Murray JL. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 53(6):490-6, 2004. PMID: 14740174.
30. Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL. Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues. Cancer Treat Rev 30(2):165-72, 2004. PMID: 15023434.
31. Ko BK, Efferson CL, Kawano K, Kuerer HM, Sahin A, Murray JL, Ioannides CG. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes. Int J Oncol 24(6):1413-8, 2004. PMID: 15138582.
32. Tsimberidou AM, Murray JL, O'Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer 100(10):2195-200, 2004. PMID: 15139064.
33. Trent JO, Wang ZX, Murray JL, Shao W, Tamamura H, Fujii N, Peiper SC. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem 278(47):47136-44, 11/2003. e-Pub 9/2003. PMID: 12958314.
34. Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res 9(7):2426-34, 2003. PMID: 12855614.
35. Ibrahim NK, Murray JL. Clinical development of the STn-KLH vaccine (Theratope). Clin Breast Cancer 3 Suppl 4:S139-43, 2003. PMID: 12620151.
36. Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG. Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 9(9):3222-34, 2003. PMID: 12960107.
37. Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL, Hortobagyi GN. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 21(18):3454-61, 2003. PMID: 12972520.
38. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 21(7):1263-70, 2003. PMID: 12663713.
39. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 8(11):3360-8, 2002. PMID: 12429622.
40. Kuerer HM, Peoples GE, Sahin AA, Murray JL, Singletary SE, Castilleja A, Hunt KK, Gershenson DM, Ioannides CG. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. J Interferon Cytokine Res 22(5):583-92, 2002. PMID: 12060497.
41. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99(12):4336-42, 2002. PMID: 12036859.
42. Esmaeli B, Murray JL, Ahmadi MA, Naderi A, Singh S, Romaguera J, White CA, McLaughlin P. Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit. Arch Ophthalmol 120(9):1225-7, 2002. PMID: 12215104.
43. Castilleja A, Carter D, Efferson CL, Ward NE, Kawano K, Fisk B, Kudelka AP, Gershenson DM, Murray JL, O'Brian CA, Ioannides CG. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex. J Immunol 169(7):3545-54, 2002. PMID: 12244144.
44. Ibrahim NK, Rahman Z, Valero V, Murray JL, Frye D, Hortobagyi GN. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. Cancer Invest 20(1):29-37, 2002. PMID: 11852999.
45. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20(7):1800-8, 2002. PMID: 11919237.
46. Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8(11):3407-18, 2002. PMID: 12429628.
47. Castilleja A, Ward NE, O'Brian CA, Swearingen B, 2nd, Swan E, Gillogly MA, Murray JL, Kudelka AP, Gershenson DM, Ioannides CG. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity. Mol Cell Biochem 217(1-2):21-33, 2001. PMID: 11269662.
48. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14):3422-33, 2001. PMID: 11454891.
49. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92(7):1775-82, 2001. PMID: 11745249.
50. Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FJ, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC, Jr, Hortobagyi GN. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19(6):1716-22, 2001. PMID: 11251001.
51. Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, Batson E, Reynolds TC, Murray JL. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 7(5):1237-45, 2001. PMID: 11350889.
52. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest 19(5):459-66, 2001. PMID: 11458813.
53. Murray JL, Przepiorka D, Ioannides CG. Clinical trials of HER-2/neu-specific vaccines. Semin Oncol 27(6 Suppl 11):71-5; discussion 92-100, 2000. PMID: 11236031.
54. Lee TV, Anderson BW, Peoples GE, Castilleja A, Murray JL, Gershenson DM, Ioannides CG. Identification of activated tumor antigen-reactive CD8+ cells in healthy individuals. Oncol Rep 7(3):455-66, 2000. PMID: 10767352.
55. Anderson BW, Kudelka AP, Honda T, Pollack MS, Gershenson DM, Gillogly MA, Murray JL, Ioannides CG. Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. Cancer Immunol Immunother 49(9):459-68, 2000. PMID: 11092612.
56. Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 26(4):269-86, 2000. PMID: 10913382.
57. Murray JL. Monoclonal antibody treatment of solid tumors: a coming of age. Semin Oncol 27(6 Suppl 11):64-70; discussion 92-100, 2000. PMID: 11236030.
58. Anderson BW, Peoples GE, Murray JL, Gillogly MA, Gershenson DM, Ioannides CG. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin Cancer Res 6(11):4192-200, 2000. PMID: 11106231.
59. Murray JL, Hudson JM, Ross MI, Zhang HZ, Ioannides CG. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression. J Immunother 23(1):28-35, 2000. PMID: 10687135.
60. Lee TV, Kim DK, Peoples GE, Castilleja A, Murray JL, Gershenson DM, Ioannides CG. Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides. J Interferon Cytokine Res 20(4):391-401, 2000. PMID: 10805374.
61. Kim DK, Lee TV, Castilleja A, Anderson BW, Peoples GE, Kudelka AP, Murray JL, Sittisomwong T, Wharton JT, Kim JW, Ioannides CG. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. Anticancer Res 19(4B):2907-16, 1999. PMID: 10652572.
62. Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res 5(5):953-61, 1999. PMID: 10353726.
63. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, Bast R, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 86(7):1251-7, 1999. PMID: 10506711.
64. Peoples GE, Anderson BW, Lee TV, Murray JL, Kudelka AP, Wharton JT, Ioannides CG. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Clin Cancer Res 5(12):4214-23, 1999. PMID: 10632363.
65. Pride MW, Shuey S, Grillo-Lopez A, Braslawsky G, Ross M, Legha SS, Eton O, Buzaid A, Ioannides C, Murray JL. Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin Cancer Res 4(10):2363-70, 1998. PMID: 9796966.
66. Hudson JM, Castilleja A, Murray JL, Honda T, Kudelka A, Singletary E, Wharton JT, Ioannides CG. Growth and antigen recognition of tumor-infiltrating lymphocytes from human breast cancer. J Interferon Cytokine Res 18(7):529-36, 1998. PMID: 9712369.
67. Saleh MN, Lalisan DY, Jr, Pride MW, Solinger A, Mayo MS, LoBuglio AF, Murray JL. Immunologic response to the dual murine anti-Id vaccine Melimmune-1 and Melimmune-2 in patients with high-risk melanoma without evidence of systemic disease. J Immunother 21(5):379-88, 1998. PMID: 9789200.
68. Babcock B, Anderson BW, Papayannopoulos I, Castilleja A, Murray JL, Stifani S, Kudelka AP, Wharton JT, Ioannides CG. Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex. Mol Immunol 35(17):1121-33, 1998. PMID: 10395201.
69. Tuttle TM, Anderson BW, Thompson WE, Lee JE, Sahin A, Smith TL, Grabstein KH, Wharton JT, Ioannides CG, Murray JL. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin Cancer Res 4(8):2015-24, 1998. PMID: 9717833.
70. Tuttle TM, Thompson WE, Anderson BW, Lee JE, Grabstein KW, Murray JL, Warton JT, Ioannides CG. A HER-2/neu peptide induces Th1 responses in associations with HLA-DR4 in breast cancer patients. Journal of Allergy and Clinical Immunology 99(1):546, 1997.
71. Macey DJ, Grant EJ, Kasi L, Rosenblum MG, Zhang HZ, Katz RL, Rieger PT, LeBherz D, South M, Greiner JW, Schlom J, Podoloff DA, Murray JL. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. Clin Cancer Res 3(9):1547-55, 1997. PMID: 9815842.
72. Fisk B, Hudson JM, Kavanagh J, Wharton JT, Murray JL, Ioannides CG, Kudelka AP. Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res 17(1A):45-53, 1997. PMID: 9066629.
73. Fisk B, Anderson BW, Gravitt KR, O'Brian CA, Kudelka AP, Murray JL, Wharton JT, Ioannides CG. Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes. Cancer Res 57(1):87-93, 1997. PMID: 8988046.
74. Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S. Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study. J Immunother 20(1):79-87, 1997. PMID: 9101417.
75. Sirisriro R, Podoloff DA, Patt YZ, Curley SA, Kasi LP, Bhadkamkar VA, Kim EE, Murray JL, Smith R, Haynie TP. 99Tcm-IMMU4 imaging in recurrent colorectal cancer: efficacy and impact on surgical management. Nucl Med Commun 17(7):568-76, 1996. PMID: 8843115.
76. Rosenblum MG, Cheung L, Kim SK, Mujoo K, Donato NJ, Murray JL. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells. Cancer Immunol Immunother 42(2):115-21, 1996. PMID: 8620520.
77. Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol 19(3):206-17, 1996. PMID: 8811495.
78. Rosenblum MG, Cheung L, Mujoo K, Murray JL. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. Cancer Immunol Immunother 40(5):322-8, 1995. PMID: 7600565.
79. Fisk B, Savary C, Hudson JM, O'Brian CA, Murray JL, Wharton JT, Ioannides CG. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction. J Immunother Emphasis Tumor Immunol 18(4):197-209, 1995. PMID: 8680648.
80. Murray JL, Macey DJ, Grant EJ, Rosenblum MG, Kasi LP, Zhang HZ, Katz RL, Riger PT, LeBherz D, Bhadkamkar V, et al. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. Cancer Res 55(23 Suppl):5925s-5928s, 1995. PMID: 7493372.
81. Mujoo K, Cheung L, Murray JL, Rosenblum MG. Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin. Cancer Immunol Immunother 40(5):339-45, 1995. PMID: 7600567.
82. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper MA, Grasela D, Buzdar A, Valero V, Booser D, Whealin H, Collins TJ, Pursley JM, Hortobagyi G. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 55(14):3060-7, 1995. PMID: 7606728.
83. Rosenblum MG, Levin B, Roh M, Hohn D, McCabe R, Thompson L, Cheung L, Murray JL. Clinical pharmacology and tissue disposition studies of 131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88. Cancer Immunol Immunother 39(6):397-400, 1994. PMID: 8001027.
84. Murray JL, Rosenblum MG, Zhang HZ, Podoloff DA, Kasi LP, Curley SA, Chan JC, Roh M, Hohn DC, Brewer H. Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. Cancer 73(3 Suppl):850-7, 1994. PMID: 8306270.
85. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS, Legha SS, Ater JL, Jaffe N, Itoh K, Ross MI, Bucana CD, Thompson L, Cheung L, Rosenblum MG. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12(1):184-93, 1994. PMID: 8270976.
86. Murray JL, Macey DJ, Kasi LP, Rieger P, Cunningham J, Bhadkamkar V, Zhang HZ, Schlom J, Rosenblum MG, Podoloff DA. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer 73(3 Suppl):1057-66, 1994. PMID: 8306248.
87. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper M, Greene D, Booser D, Buzdar A, Greiner J, Schiom J, Podoloff D. Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study. Adv Exp Med Biol 353:193-202, 1994. PMID: 7985538.
88. Goodman GE, Hellstrom I, Yelton DE, Murray JL, O'Hara S, Meaker E, Zeigler L, Palazollo P, Nicaise C, Usakewicz J, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 36(4):267-73, 1993. PMID: 8382560.
89. Mujoo K, Donato NJ, Lapushin R, Rosenblum MG, Murray JL. Tumor necrosis factor alpha and gamma-interferon enhancement of anti-epidermal growth factor receptor monoclonal antibody binding to human melanoma cells. J Immunother 13(3):166-74, 1993. PMID: 8471591.
90. Murray JL, Wilmanns C, Mujoo K, Janus MA, Rosenblum MG. Factors influencing in vivo localization of radiolabeled anti-melanoma monoclonal antibody combinations compared to single antibodies. Antibody Immunoconj Radiopharm 5:209-225, 1992.
91. Schilling PJ, Murray JL, Markowitz AB. Novel tumor necrosis factor toxic effects. Pulmonary hemorrhage and severe hepatic dysfunction. Cancer 69(1):256-60, 1992. PMID: 1309306.
92. Taddei-Peters WC, Haspel MV, Vente P, Murray JL, Cleary KR, Levin B, Paris EM, Pomato N, Murray JH, Weidman D, Hanna MG, McCabe RP. Quantitation of human tumor-reactive monoclonal antibody 16.88 in the circulation and localization of 16.88 in colorectal metastatic tumor tissue using murine antiidiotypic antibodies. Cancer Res 52(9):2603-9, 1992. PMID: 1568227.
93. Zhang HZ, Scanlon M, Murray JL, Chan JC. Substrate preference of metalloproteinases secreted by ts-110 Moloney murine sarcoma virus-transformed normal rat kidney cells. Biochem Biophys Res Commun 189(1):21-6, 1992. PMID: 1449476.
94. Rosenblum MG, Murray JL, Cheung L, Rifkin R, Salmon S, Bartholomew R. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. Mol Biother 3(1):6-13, 1991. PMID: 1906286.
95. Itoh K, Hayakawa K, Salmeron MA, Legha SS, Murray JL, Talpaz M, Balch CM, Parkinson DR, Lee K, Zukiwski AA. Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy. Cancer Immunol Immunother 33(4):238-46, 1991. PMID: 2059968.
96. Rosenblum MG, Cheung L, Murray JL, Bartholomew R. Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance. Cancer Commun 3(1):21-7, 1991. PMID: 1989645.
97. Mansfield PF, Rosenblum MG, Murray JL, Itoh K. Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody. Cancer Immunol Immunother 33(4):247-54, 1991. PMID: 1829394.
98. Mujoo K, Rosenblum MG, Murray JL. Augmented binding of radiolabeled monoclonal antibodies to melanoma cells using specific antibody combinations. Cancer Res 51(11):2768-72, 1991. PMID: 2032216.
99. Rosenblum, MG, Kavanagh JJ, Burke TW, Wharton JT, Cunningham JE, Shanken LJ, Silva EG, Thompson L, Cheung L, Murray JL. Clinical pharmacology, metabolism and tissue distribution of 90Y-labeled B72.3 after intraperitoneal administration. J Nat Cancer Inst 83:1629-1636, 1991.
100. Itoh K, Balch CM, Murray JL, Parkinson DR, Markowitz AB, Talpaz M, Lee K, Zukiwski AA, Ross MI, Legha SS, et al. Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. In Vivo 5(6):647-53, 1991. PMID: 1810451.
101. Lamki LM, Buzdar AU, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L, Podoloff DA, Zukiwski A, Hortobagyi GN, Murray JL. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med 32(7):1326-32, 1991. PMID: 2066785.
102. Murray JL, Rosenblum MG. Modulation of melanoma antigens by interferons. Cancer Treat Res 54:153-67, 1991. PMID: 1709037.
103. Chan JC, Scanlon M, Zhang HZ, Murray JL. Temperature-sensitive synthesis of a metalloproteinase in ts110-MSV-M-transformed NRK cells. Biochem Biophys Res Commun 178(2):453-9, 1991. PMID: 1859404.
104. Murray JL, Mujoo K, Wilmanns C, Mansfield P, Wilbur DS, Rosenblum MG. Variables influencing tumor uptake of anti-melanoma monoclonal antibodies radioiodinated using para-iodobenzoyl (PIB) conjugate. J Nucl Med 32(2):279-87, 1991. PMID: 1992032.
105. Abdel-Nabi HH, Levine G, Lamki LM, Murray JL, Tauxe WN, Shah AN, Patt YZ, Doerr RJ, Klein HA, Gona J, Rosenblum MJ, Unger MJ, Smith LM, Schweighardt SA, Merchant ED. Colorectal carcinoma metastases: detection with In-111-labeled monoclonal antibody CCR 086. Radiology 176(1):117-22, 1990. PMID: 2353080.
106. NishikawaK, Neuman RA, Murray JL, Khokhar AR, Rosenblum MG. Detection of cellular platinum using the monoclonal antibody 1C1. Molec Biother 2(4):235-241, 1990.
107. Patt YZ, Lamki LM, Shanken J, Jessup JM, Charnsangavej C, Ajani JA, Levin B, Merchant B, Halverson C, Murray JL. Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol 8(7):1246-54, 1990. PMID: 2193120.
108. Lamki LM, Patt YZ, Murray JL. In-111 monoclonal antibody immunoscintigraphy of colorectal cancer. Cancer Treat Res 51:293-312, 1990. PMID: 1977451.
109. Frost H, Murray JL, Chaudri HA, Van Damme J. Interleukin-6 induction by a muramyltripeptide derivative in cancer patients. J Biol Response Mod 9(2):160-6, 1990. PMID: 2341859.
110. Lamki LM, Patt YZ, Rosenblum MG, Shanken LJ, Thompson LB, Schweighardt SA, Frincke JM, Murray JL. Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody. Radiology 174(1):147-51, 1990. PMID: 2294542.
111. Rosenblum MG, Murray JL, Stuckey S, Newman RA, Chaney S, Khokhar AR. Modification of methyliminodiacetato-trans-R,R-1,2-diamminocyclohexane platinum(II) pharmacology using a platinum-specific monoclonal antibody. Cancer Chemother Pharmacol 25(6):405-10, 1990. PMID: 2311167.
112. Lamki LM, Zukiwski AA, Shanken LJ, Legha SS, Benjamin RS, Plager CE, Salk DF, Schroff RW, Murray JL. Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen. Cancer Res 50(3 Suppl):904s-908s, 1990. PMID: 2297740.
113. Halpern SE, Abdel-Nabi H, Murray JL. Radioimmunoimaging. Quo vadis? Toward the imaging of tumor. J Nucl Med 31(8):1436-8, 1990. PMID: 2384816.
114. Murray JL, Zukiwski AA, Mujoo K, Rosenblum MG. Recombinant alpha-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo. J Biol Response Mod 9(6):556-63, 1990. PMID: 2074442.
115. Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 49(16):4665-70, 1989. PMID: 2787207.
116. McCready DR, Price J, Balch CM, Murray JL. Altered biodistribution of indium-111-labeled monoclonal antibody 96.5 to tumors and normal tissues of nude mice bearing human melanoma xenografts in visceral organs. Cancer Immunol Immunother 30(5):257-61, 1989. PMID: 2624918.
117. Lee KH, Talpaz M, Rothberg JM, Murray JL, Papadopoulos N, Plager C, Benjamin R, Levitt D, Gutterman J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study. J Clin Oncol 7(11):1726-32, 1989. PMID: 2809685.
118. McCready DR, Balch CM, Fidler IJ, Murray JL. Lack of comparability between binding of monoclonal antibodies to melanoma cells in vitro and localization in vivo. J Natl Cancer Inst 81(9):682-7, 1989. PMID: 2709424.
119. Hersh EM, Murray JL, Hong WK, Rosenblum MG, Reuben JM, Weilbaecher R, Sarwal AN, Bradley EC, Konrad M, Arnett FC. Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection. Biotherapy 1(3):215-26, 1989. PMID: 2642025.
120. Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU, Fidler I, Krakoff I. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 7(12):1915-25, 1989. PMID: 2479721.
121. Frontiera M, Murray JL, Lamki L, Thomas J, Satterlee W, Schmelter R, Rosenblum MG, Khazaeli MB, Unger MW, Robinson WA. Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma. Clin Nucl Med 14(5):357-66, 1989. PMID: 2656042.
122. Murray JL, Stuckey SE, Pillow JK, Rosenblum MG, Gutterman JU. Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigens. J Biol Response Mod 7(2):152-61, 1988. PMID: 3129542.
123. Lamki LM, Murray JL, Rosenblum MG, Patt YZ, Babaian R, Unger MW. Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of 111indium labelled (MoAb). Nucl Med Commun 9(8):553-64, 1988. PMID: 3173914.
124. Murray JL, Lamki LM, Shanken LJ, Blake ME, Plager CE, Benjamin RS, Schweighardt S, Unger MW, Rosenblum MG. Immunospecific saturable clearance mechanisms for indium-111-labeled anti-melanoma monoclonal antibody 96.5 in humans. Cancer Res 48(15):4417-22, 1988. PMID: 3390837.
125. Patt YZ, Lamki LM, Haynie TP, Unger MW, Rosenblum MG, Shirkhoda A, Murray JL. Improved tumor localization with increasing dose of indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. J Clin Oncol 6(8):1220-30, 1988. PMID: 3045263.
126. Murray JL, Mehta K, Lopez-Berestein G. Induction of adenosine deaminase and 5' nucleotidase activity in cultured human blood monocytes and monocytic leukemia (THP-1) cells by differentiating agents. J Leukoc Biol 44(3):205-11, 1988. PMID: 2842422.
127. Rosenblum MG, Lamki LM, Murray JL, Carlo DJ, Gutterman JU. Interferon-induced changes in pharmacokinetics and tumor uptake of 111In-labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 80(3):160-5, 1988. PMID: 3346909.
128. Murray JL, Unger MW. Radioimmunodetection of cancer with monoclonal antibodies: current status, problems, and future directions. Crit Rev Oncol Hematol 8(3):227-53, 1988. PMID: 3048746.
129. Murray JL, Lamki LM, Rosenblum MG. Radioimmunoimaging of malignant melanoma with monoclonal antibodies. Cancer Treat Res 43:123-53, 1988. PMID: 2908570.
130. Murray JL, Reuben JM, Smith TL, Gehan EA, Koretz SM, Hersh EM. A pilot clinical trial of the toxicity and immunorestorative effects of T cell reconstituting factor (SR 270258) in immunosuppressed cancer patients. J Biol Response Mod 6(1):56-68, 1987. PMID: 2951501.
131. Murray JL, Rosenblum MG, Lamki L, Glenn HJ, Krizan Z, Hersh EM, Plager CE, Bartholomew RM, Unger MW, Carlo DJ. Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018. J Nucl Med 28(1):25-33, 1987. PMID: 3794809.
132. Rosenblum MG, Murray JL, Lamki L, David G, Carlo D. Comparative clinical pharmacology of [111In]-labeled murine monoclonal antibodies. Cancer Chemother Pharmacol 20(1):41-7, 1987. PMID: 3621452.
133. Murray JL, Bywaters DW, Reuben JM, Mansell PW, Hersh EM. Decreased 5'-nucleotidase activity in suppressor (OKT8) T lymphocytes from homosexuals with AIDS-related complex: nonassociation with enhanced deoxynucleoside toxicity. Clin Immunol Immunopathol 42(1):10-7, 1987. PMID: 3024891.
134. Murray JL, Rosenblum MG, Lamki L, Haynie TP, Glenn HJ, Plager CE, Unger MW, Carlo DJ, Hersh EM. Radioimmunoimaging in malignant melanoma patients with the use of indium-111-labeled antimelanoma monoclonal antibody (ZME-018) to high-molecular-weight antigen. NCI Monogr(3):3-9, 1987. PMID: 3821916.
135. Babaian RJ, Murray JL, Lamki LM, Haynie TP, Hersh EM, Rosenblum MG, Glenn HJ, Unger MW, Carlo DJ, von Eschenbach AC. Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276. J Urol 137(3):439-43, 1987. PMID: 3820371.
136. McCready DR, Murray JL, Balch CM, Fidler IJ. Site of metastasis influences monoclonal antibody uptake by human melanoma xenografts in nude mice. Surgical Forum 38:443-445, 1987.
137. Murray JL, Perez-Soler R, Bywaters D, Hersh EM. Decreased adenosine deaminase (ADA) and 5'nucleotidase (5NT) activity in peripheral blood T cells in Hodgkin disease. Am J Hematol 21(1):57-66, 1986. PMID: 3010705.
138. Murray JL, Dowd J, Hersh EM. In vitro inhibition of interleukin-2 production by peripheral blood lymphocytes from stage III melanoma patients by prostaglandin E2: enhancement of lymphocyte proliferation by exogenous interleukin-2 plus indomethacin. J Biol Response Mod 5(1):12-9, 1986. PMID: 3485703.
139. Hutchins MR, Slease RB, Murray JL, Gawith KE, Grozea PN. Abnormal immunoregulation in remission Hodgkin disease. Am J Hematol 20(2):119-28, 1985. PMID: 2931021.
140. Murray JL, Hersh EM, Reuben JM, Munn CG, Mansell PW. Abnormal lymphocyte response to exogenous interleukin-2 in homosexuals with acquired immune deficiency syndrome (AIDS) and AIDS related complex (ARC). Clin Exp Immunol 60(1):25-30, 1985. PMID: 3924451.
141. Hromas RA, Srigley J, Murray JL. Clinical and pathological comparison of young adult women with hepatocellular carcinoma with and without exposure to oral contraceptives. Am J Gastroenterol 80(6):479-85, 1985. PMID: 2408465.
142. Murray JL, Loftin KC, Munn CG, Reuben JM, Mansell PW, Hersh EM. Elevated adenosine deaminase and purine nucleoside phosphorylase activity in peripheral blood null lymphocytes from patients with acquired immune deficiency syndrome. Blood 65(6):1318-24, 1985. PMID: 3922455.
143. Reuben JM, Hersh EM, Murray JL, Munn CG, Mehta SR, Mansell PW. IL-2 production and response in vitro by the leukocytes of patients with acquired immune deficiency syndrome. Lymphokine Res 4(2):103-16, 1985. PMID: 2987624.
144. Murray JL, Reuben JM, Munn CG, Newell G, Mansell PW, Hersh EM. In vitro modulation of purine enzyme metabolism and lymphocyte surface marker expression by thymosin fraction 5 in homosexual males. Int J Immunopharmacol 7(5):661-9, 1985. PMID: 2995264.
145. Krizan Z, Murray JL, Hersh EM, Rosenblum MG, Glenn HJ, Gschwind CR, Carlo DJ. Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinants. Cancer Res 45(10):4904-9, 1985. PMID: 2411391.
146. Rosenblum MG, Murray JL, Haynie TP, Glenn HJ, Jahns MF, Benjamin RS, Frincke JM, Carlo DJ, Hersh EM. Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma. Cancer Res 45(5):2382-6, 1985. PMID: 3986780.
147. Murray JL, Rosenblum MG, Sobol RE, Bartholomew RM, Plager CE, Haynie TP, Jahns MF, Glenn HJ, Lamki L, Benjamin RS, Papadopoulos N, Boddie AW, Frincke JM, David GS, Carlo DJ, Hersh EM. Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5. Cancer Res 45(5):2376-81, 1985. PMID: 3986779.
148. Moldawer NP, Murray JL. The clinical uses of monoclonal antibodies in cancer research. Cancer Nurs 8(4):207-13, 1985. PMID: 3850786.
149. Whisler RL, Murray JL, Roach RW, Balcerzak SP. Characterization of multiple immune defects in human malignant lymphoma. Cancer 53(12):2628-34, 1984. PMID: 6232994.
150. Murray JL, Reuben JM, Munn CG, Mansell PW, Newell GR, Hersh EM. Decreased 5' nucleotidase activity in lymphocytes from asymptomatic sexually active homosexual men and patients with the acquired immune deficiency syndrome. Blood 64(5):1016-21, 1984. PMID: 6091811.
151. Murray JL, Lee ET. Decreased monocyte antibody-dependent cell-mediated toxicity in stage I-II malignant melanoma. Augmentation by subcutaneous Corynebacterium parvum. Cancer Immunol Immunother 17(1):66-8, 1984. PMID: 6563946.
152. Rose VL, Keppen MD, Eichner ER, Pitha JV, Murray JL. Acute leukemia after successful chemotherapy for oat cell carcinoma. Am J Clin Pathol 79(1):122-4, 1983. PMID: 6295134.
153. Sahm DF, Murray JL, Munson PL, Nordquist RE, Lerner MP. Gamma-glutamyltranspeptidase levels as an aid in the management of human cancer. Cancer 52(9):1673-8, 1983. PMID: 6137275.
154. Murray JL, Ishmael DR, Bottomley RH, Grozea PN, Lee ET. Inefficacy of sc Corynebacterium parvum in stage I malignant melanoma: preliminary results of a single-institution pilot study. Cancer Treat Rep 67(2):191-2, 1983. PMID: 6825130.
155. Murray JL, Kollmorgen GM. Inhibition of lymphocyte response by prostaglandin-producing suppressor cells in patients with melanoma. J Clin Immunol 3(3):268-76, 1983. PMID: 6224806.
156. Murray JL. Primary malignant melanoma metastatic to vitreous humor of the eye: treatment with BCNU. South Med J 76(4):523-6, 1983. PMID: 6836373.
157. Lee ET, Ishmael DR, Bottomley RH, Murray JL. An analysis of skin tests and their relationship to recurrence and survival in stage III and stage IV melanoma patients. Cancer 49(11):2336-41, 1982. PMID: 7074548.
158. Murray JL, Lerner MP, Nordquist RE. Elevated gamma-glutamyl transpeptidase levels in malignant melanoma. Cancer 49(7):1439-43, 1982. PMID: 6120756.
159. Murray JL. Prostaglandin E2 modulation of human monocyte antibody-dependent cell-mediated cytotoxicity against human red blood cells. Cell Immunol 71(1):196-201, 1982. PMID: 7139718.
160. Whisler RL, Balcerzak SP, Murray JL. Heterogeneous mechanisms of imparied lymphocyte responses in non-Hodgkin's lymphoma. Blood 57(6):1081-7, 1981. PMID: 6452921.
161. Robertson DM, Wilkinson CP, Murray JL, Gordy DD. Metastatic tumor to the retina and vitreous cavity from primary melanoma of the skin: treatment with systemic and subconjunctival chemotherapy. Ophthalmology 88(12):1296-1301, 1981. PMID: 7322479.
162. Murray JL, Hurtubise PE, Young DC, Balcerzak SP, Lobuglio AF. Correlation of prognostic factors and blood lymphocyte subtypes in non-Hodgkin's lymphoma. Cancer 46(8):1817-24, 1980. PMID: 6159065.
163. Murray JL, Schosser RH, Bottomley RH. Malignant melanoma: current trends and future prospects. J Okla State Med Assoc 73(11):377-81, 1980. PMID: 7431141.


1. Le Du F, Fujii T, Davis D, Wu Weiguo, Jackson SA, Chavez-MacGregor M, Barcenas C, Brewster AM, Murray JL, Valero V, Tripathy D, Reuben JM, Ueno NT. EpCAM-Independent Isolation of Circulating Tumor Cells with EMT phenotye in patients with primary breast cancer who receive primary systemic therapy. Journal of Clinical Oncology 2015 ASCO Annual Meeting Volume 33(15S, Part I of II):588s (#11034), 5/2015.
2. Matsuda N, Krishnamurthy S, Willey JS, Xiaoping W, Lim B, Parker CA, Wood AL, Alvarez RH, Booser DJ, Murray JL, Arun BK, Brewster A, Reuben JM, Woodward W, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed fy FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer. Journal of Clinical Oncology 2015 ASCO Annual Meeting 33(15S, Paer I of II):61s (#1065), 5/2015.
3. Zahi M, Karakas K, Ibrahim NK, Alvarez RH, Murray JL, Briones B, Simmons H, Keyomarsi K, Moulder SL. A phase I study of dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple-negative breast cancer. J Clin Oncol 32(Suppl 26) (#163), 2014.
4. Schneble EJ, Perez SA, Murray JL, Berry JS, Trappey AF, Vreeland TJ, Hale DF, Greene JM, Clifton GT, Ardavanis A, Litton JK, Ponniah S, Shumway NM, Papamichail M, Peoples GE, Mitterndorf EA,. Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients. J Clin Oncol 32(Suppl 26) (#134), 2014.
5. Anastasopoulou EA, Pappou E, Tzonis P, Ardavnis A, Ponniah S, Baxevanis CN, Murray JL,. Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study. J Clin Oncol(31) (#3095), 2013.
6. Pusztai L, Mattair D, Ueno NT, Valero V, Moulder SL, Murray, JL, Alvarez RH, Chavez-MacGregor M, Santiago L, Avritscher R, Sahin AA, Hortobagyi GN, Symmans WF, Meric-Bernstam F, Burton EM, Gonzalez-Angulo AM,. Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection. J Clinc Oncol(31) (#532), 2013.
7. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 8/2012. PMID: 23053261.
8. Mittendorg EA, Preez SA, Hale DF, Vreeland TJ, Sears AK, Clifton GT, Ardavanis A, Shumway NM, Murray JL, Ponniah S, Papamichail M, Peoples GE. Early efficacy analysis of the AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer. J Clin Oncol 30 (#109), 2012.
9. Murthy RK, Varma A, Mishra P, Hess KR, Young EJ, Murray JL, Koenig K, Green MC, Moulder SL, Melhem-Bertrandt A, Booser DJ, Valero V, Hortobagyi GN, Esteva FJ. Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting. J Clin Oncol 30 (#527), 2012.
10. Basen-Engquist K, Murray JL, Baum G, Gutierrz-Barrera A, Arun B. Randomized pilot study of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy. J Clin Oncol (#e11090), 2012.
11. Murray JL, Thompson P, Zhou R, Yoo SY, Liu Y, D KA, Sahin A, Bondy M, Brewster A. Prognostic value of single nucleotide polymorphisms (SNPs) of candidate genes associated with inflammation in early stage breast cancer. Journal of Clinical Oncology 29:Suppl. Abstract 1524, 2011.
12. Chen JQ, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Sahin A, Katz R, Murray JL, Radvanyi L. Quantitative Immunohistochemical Analysis and Prognostic Significance of TRPS-1, a new GATA transcription Factor Family Member, in Breast Cancer. San Antonio Breast Cancer Symposium 2010, 12/2010.
13. Murray JL, Thompson PA, Tuna M, Brewster A, Edgerton ME, Tsachavidis S, Do KA, Wang Y, Yun SJ, Zhang L, Sahin A, Mills GB, Bondy M,. Association of gene copy number aleterations in formalin-fixed, paraffin-embedded tumors with prognostic molecular and pathological subtypes in early-stage breast cancer. Proceeding of ASCO 2010 (#572), 6/2010.
14. Brewster AM, Thompson PA, Do KA, Sahin A, Zhang L, Murray JL, Tsachavidis S, Mills GB, Bondy M. Investigation of ethnic differences in the prevalence of chromosomal number aberrations of luminal and triple-negative breast cancers associated with risk of recurrence. Proceedings of ASCO 2010 (#1526), 6/2010.
15. Thompson PA, Do KA, Brewster AM, Tsavachidis S, Sahin AA, Murray JL, Mills GB, Bondy ML. Specific copy number imbalances add to predictor of early stage breast cancer recurrence based on intrinsic subtypes. Proceeding of ASCO 2010, 6/2010.
16. Bambhroliya A, Bondy M, Thompson P, Sahin A, Murray JL, Zhou R, Sexton K, Brewster AM,. Epidemiologic risk factors associated with breast cancer subtypes. Proceeding of ASCO 2010 (#1585), 2010.
17. Basen-Engquist K, Perkins H, Carmac C, Hughes D, Jovanovic J, Arun B, Murray JL. Test of a weight gain prevention intervention in stage II and III breast cancer patients receiving neoadjuvant chemotherapy. Cancer, Epidemiology, Biomarkers, & Prevention 19(3):895-896, 2010.

Last updated: 4/29/2016